Daniel W. Bowles
A5088419169- Thyroid Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Head and Neck Cancer Studies
- Melanoma and MAPK Pathways
- Synthesis and biological activity
- Tumors and Oncological Cases
- Cancer, Hypoxia, and Metabolism
- S100 Proteins and Annexins
- PI3K/AKT/mTOR signaling in cancer
- Hedgehog Signaling Pathway Studies
- Chronic Lymphocytic Leukemia Research
- Ear and Head Tumors
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Biochemical and Molecular Research
- Oral and Maxillofacial Pathology
- COVID-19 and healthcare impacts
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer-related gene regulation
- Nutrition, Genetics, and Disease
- Bladder and Urothelial Cancer Treatments
University of Colorado Anschutz Medical Campus
2017-2024
University of Colorado Denver
2015-2024
University of Colorado Cancer Center
2012-2024
University of Colorado Hospital
2023-2024
University of Colorado Health
2023
Dana-Farber Cancer Institute
2023
National Cancer Center
2023
Michigan United
2023
University of California, Los Angeles
2023
Seoul National University Hospital
2023
Abstract Purpose: To define the genetic landscape of advanced differentiated and anaplastic thyroid cancer (ATC) identify alterations potential diagnostic, prognostic, therapeutic significance. Experimental Design: The profiles 583 196 ATCs generated with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT FoundationOne were analyzed. Results: ATC had more per tumor, pediatric papillary fewer tumor when compared other types. DNA mismatch repair deficit activity...
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort patients and 2019 (COVID-19) reported to the COVID-19 Cancer Consortium (CCC19) identify prognostic clinical factors, including laboratory measurements anticancer therapies. active or historical laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March 18 November 2020 were included. The primary outcome was severity measured...
Abstract Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of receptor tyrosine kinase. ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety patients with advanced -altered solid tumors. Twenty-nine 12 different fusion–positive tumor types, excluding non-small-cell lung cancer thyroid cancer, who had previously received or were not candidates for standard therapies, enrolled. The most common fusion partners 23...
RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective inhibitor, previously demonstrated clinical activity patients with fusion-positive NSCLC the phase I/II ARROW study, including among treatment-naive patients. We report an updated analysis from study.ARROW is multi-cohort, open-label, study. Eligible were ≥18 years age locally advanced or metastatic solid tumours and Eastern Cooperative...
Abstract Purpose: The objectives of the study were to evaluate maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity PX-866 in patients with incurable cancers. Experimental Design: This was a phase I, open-label, dose-escalation study. Drug administered orally once per day either on an intermittent (arm 1; days 1–5 8–12 28-day cycle) or continuous 2; 1–28 schedule. Additional treated at arm 2 MTD food effects substudy. Results: Eighty-four 1 (n =...
<h3>Importance</h3> Data on adjuvant concurrent chemoradiotherapy (CRT) after resection of salivary gland carcinomas (SGCs) are limited. <h3>Objective</h3> To examine overall survival (OS) outcomes patients who receive CRT vs radiotherapy (RT) alone SGCs. <h3>Design, Setting, and Participants</h3> The National Cancer Base (NCDB), a hospital-based registry that represents 70% all cancer cases in the United States, was queried for underwent major SGCs with at least 1 high-risk feature (T3-T4...
We sought to identify genomic alterations (GA) in salivary gland adenocarcinomas, not otherwise specified (NOS), duct carcinomas (SDC), carcinoma ex pleomorphic adenoma (ca PA), and carcinoma, NOS.DNA was extracted from 149 tumors. Comprehensive profiling (CGP) performed on hybridization-captured adaptor ligation-based libraries of 182 or 315 cancer-related genes plus introns 14 28 frequently rearranged for cancer evaluated all classes GAs.A total 590 GAs were found 157 unique (mean...
•Pertuzumab + trastuzumab produced a response in 60% (9/15) of patients with HER2-amplified/overexpressing salivary cancer.•Stable disease was observed patient HER2-mutated cancer treated pertuzumab trastuzumab.•Vismodegib, vemurafenib, and atezolizumab responses tumors matched genomic alterations.•Safety for each treatment consistent previously reported safety profiles.•Results support use molecular profiling to identify effective chemotherapy-free targeted treatments cancers....
Immunotherapy for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is promising. The toll-like receptor 8 (TLR8) agonist motolimod may stimulate innate adaptive immunity.To determine whether improves outcomes R/M SCCHN when combined with standard therapy.The Active8 study was a multicenter, randomized, double-blind, placebo-controlled clinical trial enrolling adult patients (age ≥18 years) histologically confirmed oral cavity, oropharynx, hypopharynx, or...
Relapsed/metastatic salivary gland carcinomas (SGCs) have a wide diversity of histologic subtypes associated with variable clinical aggressiveness and response to local systemic therapies. We queried whether comprehensive genomic profiling could define the tumor uncover clinically relevant alterations, revealing new routes targeted therapies for patients relapsed metastatic disease.From series 85 686 cases, DNA was extracted from 40 µm formalin-fixed paraffin embedded (FFPE) sections 623...
The overall survival (OS) benefit of concurrent chemoradiotherapy (CRT) for head and neck squamous cell carcinoma patients older than 70 years is debated. This study examines the outcomes elderly receiving CRT versus radiotherapy (RT) alone.The National Cancer Data Base was queried with nonmetastatic oropharyngeal, laryngeal, or hypopharyngeal cancer (T3-4 N(+)). defined as chemotherapy started within 14 days initiation RT. Univariate analysis, multivariate analysis (MVA), propensity score...
Abstract Five-year survival for human papilloma virus-unrelated head and neck squamous cell carcinomas remain below 50%. We assessed the safety of administering combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1) neoadjuvantly ( n = 21) NCT03635164 ). The primary endpoint study was safety, which met. Secondary endpoints included radiographic, pathologic objective response; locoregional control; progression-free survival; overall survival....
PURPOSE Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk METHODS Patients had cell carcinoma of the (SCCHN) oral cavity, oropharynx, or larynx, with one more risk factors warranting postoperative RT. were randomly assigned 1:1 to intensity-modulated (60-66 Gy) once-per-week C alone. The primary hypothesis was that + would improve overall survival (OS)...